ArticleMethods in molecular biology (Clifton, N.J.)2027
Methods for Identifying Type III Secretion System Effectors in Chlamydia trachomatis.
Article in Methods in molecular biology (Clifton, N.J.), 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To subvert host defenses and establish a replicative niche, obligate intracellular pathogens remodel the host cell using a discrete repertoire of effector proteins. For Chlamydia trachomatis, defining the repertoire of conventional type III secretion system effectors (cT3SS) has been exceedingly difficult as many of these proteins are present at low levels in the host cell and do not accumulate within a specific host compartment, necessitating signal amplification for accurate detection. Drawing on approaches widely used for assessing secretion of candidate T3SS and T4SS substrates, several enzymatic reporter tags have been adapted to evaluate secretion of putative C. trachomatis cT3SS substrates. Here we describe BlaM, CyaA, and GSK assays, which are three complementary assays that provide robust and reliable readouts of effector delivery into the host cell. This protocol describes each assay in detail, including the steps required to generate C. trachomatis transformants, confirm effector-reporter expression, and execute and analyze data for each assay.
Indexed as
Identifiers
42771158What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.